Literature DB >> 28593554

Hydrocephalus and mucopolysaccharidoses: what do we know and what do we not know?

Amauri Dalla Corte1, Carolina F M de Souza2, Maurício Anés3, Roberto Giugliani4,2.   

Abstract

INTRODUCTION: The precise incidence of hydrocephalus in patients with mucopolysaccharidoses (MPS) is hard to determine, because the condition lacks a formal, consensus-based definition. The diagnosis of hydrocephalus depends on symptom profile, presence of neuroimaging features, and the outcome of diagnostic tests. Although numerous techniques are used to identify MPS patients who are most likely to have hydrocephalus and respond to treatment, no definitive method exists to prove diagnosis.
PURPOSE: The authors propose an algorithm to aid in the diagnosis and management of hydrocephalus in MPS patients.
CONCLUSIONS: The theory of venous hypertension associated with the morphological changes in the skull base and craniocervical junction indicate the need for future neuroimaging studies including cerebrospinal fluid (CSF) and venous flow measurements to monitor hydrocephalus progression and select therapeutic interventions in MPS patients. Preoperative planning should also be based on the increased risk of intraoperative and postoperative hemorrhagic complications.

Entities:  

Keywords:  Brain MRI; Hydrocephalus; Mucopolysaccharidoses; Shunt; Ventricular enlargement

Mesh:

Year:  2017        PMID: 28593554     DOI: 10.1007/s00381-017-3476-0

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  36 in total

1.  Normal pressure hydrocephalus: new concepts on etiology and diagnosis.

Authors:  W G Bradley
Journal:  AJNR Am J Neuroradiol       Date:  2000-10       Impact factor: 3.825

2.  Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation.

Authors:  M Gisele Matheus; Mauricio Castillo; J Keith Smith; Diane Armao; Diane Towle; Joseph Muenzer
Journal:  Neuroradiology       Date:  2004-06-17       Impact factor: 2.804

3.  Circulating anticoagulant glycosaminoglycans in mucopolysaccharidosis type I.

Authors:  J Tolar; P J Orchard; N S Key; B R Blazar
Journal:  J Thromb Haemost       Date:  2008-02-25       Impact factor: 5.824

4.  Computed tomography studies on patients with mucopolysaccharidoses.

Authors:  R W Watts; E Spellacy; B E Kendall; G du Boulay; D A Gibbs
Journal:  Neuroradiology       Date:  1981-02       Impact factor: 2.804

5.  Serial magnetic resonance imaging findings in mucopolysaccharidosis IIIB (Sanfilippo's syndrome B).

Authors:  D I Zafeiriou; P A Savvopoulou-Augoustidou; A Sewell; F Papadopoulou; M Badouraki; E Vargiami; N P Gombakis; G S Katzos
Journal:  Brain Dev       Date:  2001-10       Impact factor: 1.961

Review 6.  Multidisciplinary management of Hunter syndrome.

Authors:  Joseph Muenzer; M Beck; C M Eng; M L Escolar; R Giugliani; N H Guffon; P Harmatz; W Kamin; C Kampmann; S T Koseoglu; B Link; R A Martin; D W Molter; M V Muñoz Rojas; J W Ogilvie; R Parini; U Ramaswami; M Scarpa; I V Schwartz; R E Wood; E Wraith
Journal:  Pediatrics       Date:  2009-11-09       Impact factor: 7.124

7.  Disc oedema in association with Hunter's syndrome: ocular histopathological findings.

Authors:  M Beck; G Cole
Journal:  Br J Ophthalmol       Date:  1984-08       Impact factor: 4.638

8.  Communicating hydrocephalus in children with genetic inborn errors of metabolism.

Authors:  G W Fowler; M Sukoff; A Hamilton; J P Williams
Journal:  Childs Brain       Date:  1975

9.  Congenital idiopathic hydrocephalus of infancy: the results of treatment by endoscopic third ventriculostomy with or without choroid plexus cauterization and suggestions for how it works.

Authors:  Benjamin C Warf
Journal:  Childs Nerv Syst       Date:  2013-03-13       Impact factor: 1.475

Review 10.  Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.

Authors:  J Edmond Wraith; Maurizio Scarpa; Michael Beck; Olaf A Bodamer; Linda De Meirleir; Nathalie Guffon; Allan Meldgaard Lund; Gunilla Malm; Ans T Van der Ploeg; Jiri Zeman
Journal:  Eur J Pediatr       Date:  2007-11-23       Impact factor: 3.183

View more
  5 in total

1.  Successful management of MPS hydrocephalus by acetazolamide.

Authors:  Hakim Rahmoune; Nada Boutrid; Imene Gherbi; Samir Arezki; Mounira Amrane; Belkacem Bioud
Journal:  Childs Nerv Syst       Date:  2017-09-19       Impact factor: 1.475

Review 2.  Mucopolysaccharidoses: overview of neuroimaging manifestations.

Authors:  Manal Nicolas-Jilwan; Moeenaldeen AlSayed
Journal:  Pediatr Radiol       Date:  2018-05-11

3.  Correlation of CSF flow using phase-contrast MRI with ventriculomegaly and CSF opening pressure in mucopolysaccharidoses.

Authors:  Amauri Dalla Corte; Carolina F M de Souza; Maurício Anés; Fabio K Maeda; Armelle Lokossou; Leonardo M Vedolin; Maria Gabriela Longo; Monica M Ferreira; Solanger G P Perrone; Olivier Balédent; Roberto Giugliani
Journal:  Fluids Barriers CNS       Date:  2017-09-18

4.  Craniosynostosis affects the majority of mucopolysaccharidosis patients and can contribute to increased intracranial pressure.

Authors:  Esmee Oussoren; Irene M J Mathijssen; Margreet Wagenmakers; Rob M Verdijk; Hansje H Bredero-Boelhouwer; Marie-Lise C van Veelen-Vincent; Jan C van der Meijden; Johanna M P van den Hout; George J G Ruijter; Ans T van der Ploeg; Mirjam Langeveld
Journal:  J Inherit Metab Dis       Date:  2018-08-06       Impact factor: 4.982

5.  Case Report: Cerebral Revascularization in a Child With Mucopolysaccharidosis Type I.

Authors:  Nathan Grant; J Michael Taylor; Zach Plummer; Kasiani Myers; Thomas Burrow; Lori Luchtman-Jones; Anna Byars; Adrienne Hammill; Katie Wusick; Edward Smith; James Leach; Sudhakar Vadivelu
Journal:  Front Pediatr       Date:  2021-06-10       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.